(Q36445553)

14 August 2017

1 reference

title

Prevention and treatment of respiratory syncytial virus infection in infants: an update (English)

1 reference

14 August 2017

0 references

Mohan Pammi Venkatesh

series ordinal

1

1 reference

14 August 2017

Leonard E Weisman

series ordinal

2

1 reference

14 August 2017

publication date

1 April 2006

1 reference

Expert Review of Vaccines

14 August 2017

published in

1 reference

14 August 2017

volume

5

1 reference

14 August 2017

issue

2

1 reference

14 August 2017

page(s)

261-268

1 reference

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Mortality associated with influenza and respiratory syncytial virus in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Respiratory syncytial virus and parainfluenza virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Immunology of respiratory syncytial virus infection: eosinophils, cytokines, chemokines and asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

A randomized, double-blind, placebo-controlled trial of dexamethasone in severe respiratory syncytial virus (RSV) infection: effects on RSV quantity and clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Exogenous surfactant supplementation in infants with respiratory syncytial virus bronchiolitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Safety and pharmacokinetics of palivizumab therapy in children hospitalized with respiratory syncytial virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Real-time detection of virus particles and viral protein expression with two-color nanoparticle probes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Birth weight and hospital readmission of infants born prematurely

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Current respiratory syncytial virus prevention strategies in high-risk infants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

PICNIC (Pediatric Investigators Collaborative Network on Infections in Canada) study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. The Cardiac Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Cost-effectiveness of palivizumab in New Zealand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Future directions in vaccine prevention of respiratory syncytial virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

A step ahead. Infant protection through maternal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Cold-passaged, temperature-sensitive mutants of human respiratory syncytial virus (RSV) are highly attenuated, immunogenic, and protective in seronegative chimpanzees, even when RSV antibodies are infused shortly before immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Interferon gamma expressed by a recombinant respiratory syncytial virus attenuates virus replication in mice without compromising immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

An assessment of different DNA delivery systems for protection against respiratory syncytial virus infection in the murine model: gene-gun delivery induces IgG in the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Respiratory syncytial viral infection in children with compromised immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

Maternal immunization against viral disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.5.2.261

21 January 2018

Identifiers

DOI

10.1586/14760584.5.2.261

1 reference

14 August 2017

1 reference